



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	169111	GlucoPlex
ARTG entry for	Medicine Listed	
Sponsor	Herbs of Gold Pty Ltd	
Postal Address	PO Box 3143, KIRRAWEE, NSW, 2232 Australia	
ARTG Start Date	15/02/2010	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . GlucoPlex

Product Type	Single Medicine Product	Effective Date	2/02/2021
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Helps maintain/support healthy blood sugar/glucose
Aid/assist/helps glucose/sugar/carbohydrate metabolism

Indication Requirements

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form	Capsule, hard
Route of Administration	Oral

Visual Identification

Active Ingredients

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

alpha lipoic acid	200 mg
chromic chloride hexahydrate	256.3 microgram
Equivalent: chromium	50 microgram
chromium picolinate	133.5 microgram
Equivalent: chromium	16.6 microgram
Cinnamomum cassia stem bark Extract dry concentrate	66.67 mg
Equivalent: Cinnamomum cassia (Dry)	1 g
colecalfiferol	.0083 mg
Gymnema sylvestre leaf Extract dry concentrate standardised	100 mg
Equivalent: Gymnema sylvestre (Dry)	2 g
nicotinamide	35 mg
Trigonella foenum-graecum seed Extract dry concentrate	4 mg
Equivalent: Trigonella foenum-graecum (Dry)	500 mg
zinc amino acid chelate	50 mg
Equivalent: zinc	10 mg

Other Ingredients (Excipients)

Acacia
carrageenan
colloidal anhydrous silica
crospovidone
dl-alpha-tocopherol
hypromellose
magnesium stearate
maize starch
medium chain triglycerides
microcrystalline cellulose
potassium acetate
povidone
purified water
silicon dioxide
sucrose

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary